Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Benitec Biopharma Inc.
Benitec Biopharma Inc. (BNTC) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 28 SEC filings.
- Warrants outstanding
- 6 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.